Lenalidomide, doxorubicin hydrochloride and dexamethasone versus bortezomib, lenalidomide, and dexamethasone prior to scheduled stem cell transplant in newly diagnosed myeloma.

被引：3
|
作者：
Knop, Stefan
Langer, Christian
Engelhardt, Monika Martha
Wangemann, Johanne
Muegge, Lars Olof
Bassermann, Florian
Schaefer-Eckart, Kerstin
Blau, Igor W.
Wolleschak, Denise
Reichle, Albrecht
von Metzler, Ivana
Metzner, Bernd
Rollig, Christoph
Hertenstein, Bernd
Pfreundschuh, Michael
Brummendorf, Tim H.
Gramatzki, Martin
Ritgen, Mattias
Held, Swantje
Einsele, Hermann
机构：
[1] Julius Maximilians Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] Univ Klinikum Ulm, Klin Innere Med 3, Ulm, Germany
[3] Univ Freiburg, Dept Hematol & Oncol, Freiburg, Germany
[4] Schleswig Holstein Univ Hosp, Kiel, Germany
[5] Jena Univ Hosp, Jena, Germany
[6] Tech Univ Munich, Dept Med 3, Munich, Germany
[7] Nuremberg Hosp, Nurnberg, Germany
[8] Charite Campus Benjamin Franklin, Dept Internal Med 3, Berlin, Germany
[9] Magdeburg Univ Hosp, Magdeburg, Germany
[10] Regensburg Univ Hosp, Regensburg, Germany
[11] Frankfurt Univ Hosp, Frankfurt, Germany
[12] Med Campus Univ Oldenburg, Klinikum Oldenburg AoR, Oldenburg, Germany
[13] Univ Hosp Carl Gustav Carus, Dept Med 1, Dresden, Germany
[14] Klinikum Bremen Mitte, Dept Hematol & Oncol, Bremen, Germany
[15] Univ Saarland, Med Sch, Homburg, Germany
[16] Univ Klinikum RWTH Aachen, Aachen, Germany
[17] Dept Internal Med II, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany
[18] Univ Schleswig Holstein, City Hosp Kiel, Med Dept II, Kiel, Germany
[19] ClinAssess GmbH, Leverkusen, Germany
[20] Univ Hosp Wuerzburg, Dept Internal Med 2, Wurzburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8001
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
    Liang, Dong
    Bai, Shenrui
    Feng, Demei
    Chen, Guanjun
    Liang, Yang
    Wang, Hua
    [J]. BMC CANCER, 2024, 24 (01)
  • [2] Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.
    Knop, Stefan
    Langer, Christian
    Engelhardt, Monika Martha
    Bassermann, Florian
    Schreder, Martin
    Muegge, Lars-Olof
    Schaefer-Eckart, Kerstin
    Blau, Igor W.
    Wolleschak, Denise
    Reusch, Julia
    von Metzler, Ivana
    Metzner, Bernd
    Dechow, Tobias
    Hertenstein, Bernd
    Duerk, Heinz
    Theurich, Sebastian
    Stuebig, Thomas
    Kroenke, Jan
    Held, Swantje
    Einsele, Hermann
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
    Khan, Meaghan L.
    Reeder, Craig B.
    Kumar, Shaji K.
    Lacy, Marthy Q.
    Reece, Donna E.
    Dispenzieri, Angela
    Gertz, Morie A.
    Greipp, Phillip
    Hayman, Suzanne
    Zeldenhurst, Steven
    Dingli, David
    Lust, John
    Russell, Stephen
    Laumann, Kristina M.
    Mikhael, Joseph R.
    Bergsagel, P. Leif
    Fonseca, Rafael
    Rajkumar, S. Vincent
    Stewart, A. Keith
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (03) : 326 - 333
  • [4] A comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM)
    Khan, M. L.
    Reeder, C. B.
    Kumar, S.
    Lacy, M.
    Reece, D. E.
    Laumann, K. M.
    Mikhael, J.
    Fonseca, R.
    Rajkumar, V.
    Stewart, A. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Randomised, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone Followed by Ciltacabtagene Autoleucel Versus Bortezomib, Lenalidomide and Dexamethasone Followed by Lenalidomide and Dexamethasone Maintenance in Patients With Newly Diagnosed Multiple Myeloma Not Intended for Transplant: CARTITUDE-5
    Dytfeld, Dominik
    Dhakal, Binod
    Agha, Mounzer
    Manier, Salomon
    Delforge, Michel
    Kuppens, Steven
    Afifi, Salma
    Deraedt, William
    Taraseviciute-Morris, Agne
    Schecter, Jordan M.
    Gilbert, Jane
    Yalniz, Fevzi
    Florendo, Erika
    Pacaud, Lida
    Hungria, Vania
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 122 - 123
  • [6] Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma
    S Knop
    C Langer
    M Engelhardt
    L-O Mügge
    A Reichle
    W Rösler
    F Bassermann
    B Hertenstein
    A Kunitz
    C Röllig
    H Ostermann
    K Schäfer-Eckart
    M Ringhoffer
    A Günther
    C Junghanss
    H Biersack
    M Schreder
    A Liebert
    S Held
    H Einsele
    R C Bargou
    [J]. Leukemia, 2017, 31 : 1816 - 1819
  • [7] Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma
    Knop, S.
    Langer, C.
    Engelhardt, M.
    Muegge, L-O
    Reichle, A.
    Roesler, W.
    Bassermann, F.
    Hertenstein, B.
    Kunitz, A.
    Roellig, C.
    Ostermann, H.
    Schaefer-Eckart, K.
    Ringhoffer, M.
    Guenther, A.
    Junghanss, C.
    Biersack, H.
    Schreder, M.
    Liebert, A.
    Held, S.
    Einsele, H.
    Bargou, R. C.
    [J]. LEUKEMIA, 2017, 31 (08) : 1816 - 1819
  • [8] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Carlyn Rose Tan
    Andriy Derkach
    David Nemirovsky
    Amanda Ciardiello
    Benjamin Diamond
    Malin Hultcrantz
    Hani Hassoun
    Sham Mailankody
    Urvi Shah
    Kylee Maclachlan
    Dhwani Patel
    Oscar B. Lahoud
    Heather J. Landau
    David J. Chung
    Gunjan L. Shah
    Michael Scordo
    Sergio A. Giralt
    Alexander Lesokhin
    Saad Z. Usmani
    Ola Landgren
    Neha Korde
    [J]. Blood Cancer Journal, 13
  • [9] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Tan, Carlyn Rose
    Derkach, Andriy
    Nemirovsky, David
    Ciardiello, Amanda
    Diamond, Benjamin
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Maclachlan, Kylee
    Patel, Dhwani
    Lahoud, Oscar B. B.
    Landau, Heather J. J.
    Chung, David J. J.
    Shah, Gunjan L. L.
    Scordo, Michael
    Giralt, Sergio A. A.
    Lesokhin, Alexander
    Usmani, Saad Z. Z.
    Landgren, Ola
    Korde, Neha
    [J]. BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [10] Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China-Compared with bortezomib/lenalidomide/dexamethasone
    Huo, Zhongjun
    Chen, Fang
    Liu, Ping
    Luo, Zimian
    [J]. CANCER MEDICINE, 2023, 12 (03): : 2937 - 2944
12345